<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245011</url>
  </required_header>
  <id_info>
    <org_study_id>J0347 CDR0000447134</org_study_id>
    <secondary_id>JHOC-J0347</secondary_id>
    <secondary_id>JHOC-03090802</secondary_id>
    <nct_id>NCT00245011</nct_id>
  </id_info>
  <brief_title>Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma</brief_title>
  <official_title>High Dose Samarium-153 With Peripheral Blood Stem Cell Support in High Risk Osteogenic Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry
      radiation directly to tumor cells and not harm normal cells. A peripheral stem cell
      transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and
      samarium Sm 153 lexidronam pentasodium. Radiation therapy uses high-energy x-rays to kill
      tumor cells. Giving samarium Sm 153 lexidronam pentasodium together with a peripheral stem
      cell transplant and radiation therapy may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving samarium Sm 153 lexidronam
      pentasodium together with autologous stem cell transplant and radiation therapy works in
      treating patients with recurrent or refractory, metastatic, or unresectable osteosarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the clinical response in patients with recurrent or refractory, metastatic, or
           unresectable osteosarcoma treated with high-dose samarium Sm 153 lexidronam pentasodium
           (^153Sm-EDTMP) and autologous peripheral blood stem cell transplantation followed by
           external-beam radiotherapy.

        -  Correlate the amount of radiation delivered to a tumor with low-dose ^153Sm-EDTMP with
           that of high-dose ^153Sm-EDTMP in patients treated with this regimen.

      Secondary

        -  Determine the overall and progression-free survival of patients treated with this
           regimen.

        -  Determine the toxicity of this regimen in these patients.

        -  Determine the long-term effects of this regimen in these patients.

        -  Determine the predictive value of fludeoxyglucose F 18 positron emission tomography
           (FDG-PET), diffusion-weighted MRI, and magnetic resonance spectroscopy for evaluation of
           treatment response in patients treated with this regimen.

      OUTLINE: Patients are stratified according to resectability of the primary tumor (recurrent,
      refractory, or very high-risk disease vs unresectable primary tumor).

        -  Mobilization and collection of autologous peripheral blood stem cells (PBSCs)* :
           Patients receive ifosfamide IV daily for 5 days followed by filgrastim (G-CSF)
           subcutaneously daily. Patients then undergo leukapheresis for collection of autologous
           PBSCs until ≥ 2 x 10^6 CD34 (cluster of differentiation 34)-positive cells/kg are
           collected.

      NOTE: *Patients who have undergone PBSC collection before study entry proceed to high-dose
      samarium Sm 153 lexidronam pentasodium (153Sm-EDTMP) infusion without mobilization and
      collection of autologous PBSCs.

        -  153Sm-EDTMP infusion: Patients receive a trace dose of ^153Sm-EDTMP** IV over 1-2
           minutes and undergo bone scan 4, 24, and 48-72 hours later. Six weeks later, patients
           receive high-dose ^153Sm-EDTMP IV over 1-2 minutes and undergo repeat bone scans 4, 24,
           and 48-72 hours later.

      NOTE: **Patients may receive the trace dose on protocol JHOC (Johns Hopkins Oncology
      Center)-J0094.

        -  Autologous peripheral blood stem cell transplantation (PBSCT): Between 12-14 days after
           administration of high-dose ^153Sm-EDTMP, patients undergo autologous PBSCT. Beginning 2
           days later, patients receive G-CSF IV daily.

        -  External-beam radiotherapy: Patients then undergo external-beam radiotherapy to the
           sites of bulky disease.

        -  Surgery: Some patients may also undergo surgical resection of residual disease. After
           completion of study treatment, patients are followed periodically for up to 3 years.

      PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>1 week after study treatment</time_frame>
    <description>WHO (World Health Organization) tumor measurement criteria used to determine response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive Value of Imaging Studies</measure>
    <time_frame>At Time of Tumor Resection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and Progression-free Survival After Study Treatment</measure>
    <time_frame>Continual</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity at End of Study Treatment</measure>
    <time_frame>Continual and at End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Side Effects of Infusional Samarium-153 After Study Treatment</measure>
    <time_frame>Continual</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative Dose of Radiation by Low Dose and High Dose Samarium-153</measure>
    <time_frame>completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Samarium-153</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytoxan+Ifosfamide, Filgrastim pre samarium.'Sm-EDTMP (low dose). once counts recover, Sm-EDTMP (high dose) given. Peripheral blood stem cell transplantation is done 14 days later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.</description>
    <arm_group_label>Samarium-153</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Ifosfamide administered IV.</description>
    <arm_group_label>Samarium-153</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered</description>
    <arm_group_label>Samarium-153</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Sm-EDTMP (low dose)</intervention_name>
    <description>Sm-EDTMP (low dose) administered after autologous stem cell collection</description>
    <arm_group_label>Samarium-153</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>sm-EDTMP (higher dose)</intervention_name>
    <description>Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.</description>
    <arm_group_label>Samarium-153</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Diagnosis of osteosarcoma

               -  High-risk disease, meeting 1 of the following criteria:

                    -  Recurrent disease

                    -  Refractory to conventional therapy

                    -  Newly diagnosed metastatic disease with ≥ 4 pulmonary nodules or multiple
                       bone lesions

                    -  Unresectable primary tumor

               -  Prior intralesional resection allowed

          -  Measurable disease by technetium Tc 99m diphosphonate bone scan

          -  Refractory to all standard therapies or highly unlikely to respond to conventional
             treatment

          -  Performance status Karnofsky 60-100%

          -  Life expectancy more than 8 weeks

          -  Absolute neutrophil count &gt; 500/mm^3

          -  Platelet count &gt; 50,000/mm^3

          -  Creatinine clearance &gt; 70 mL/min OR * Radioisotope glomerular filtration rate normal

          -  Recovered from prior chemotherapy

        Exclusion

          -  Pregnant or nursing

          -  Positive pregnancy test for females of childbearing potential

          -  Fertile patients do not agree to use effective contraception

          -  Prior radiotherapy to the site of currently active disease

          -  Concurrent enrollment on protocol JHOC-J0094 allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Loeb, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Senthamizhchelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour E, Wahl RL, Loeb DM, Sgouros G. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med. 2012 Feb;53(2):215-24. doi: 10.2967/jnumed.111.096677. Epub 2012 Jan 17.</citation>
    <PMID>22251554</PMID>
  </results_reference>
  <results_reference>
    <citation>Loeb DM, Hobbs RF, Okoli A, Chen AR, Cho S, Srinivasan S, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer. 2010 Dec 1;116(23):5470-8. doi: 10.1002/cncr.25518. Epub 2010 Aug 16.</citation>
    <PMID>20715156</PMID>
  </results_reference>
  <results_reference>
    <citation>Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009 Jun 1;115(11):2514-22. doi: 10.1002/cncr.24286.</citation>
    <PMID>19338063</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>April 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2015</results_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>localized osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Samarium Sm-153 lexidronam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Samarium-153/Stem Cell Transplant/Radiation</title>
          <description>Samarium Sm153 Lexidronam Pentasodium (Samarium)/Stem Cell Transplant/Radiation arm: receive Ifosphamide IV in preparation for peripheral blood stem cell transplant followed by collection of stem cells. Samarium is administered after collection of peripheral blood stem cells (PBCT). Once counts recover, while receiving filgrastim daily, a second, higher dose of Samarium-153 is given, followed in 14 days by infusion of the stem cells.
Filgrastim: administered daily until count recovery Ifosfamide: administered as part of Stem Cell transplant preparation. PBCT: Before administration of Samarium, collection of autologous hematopoietic stem cells Radiation: Radiation Dosimetry performed at 4, 24, 48, and 72 after each infusion of Sm-EDTMP.
Samarium: First dose is administered after autologous stem cell collection. Second, higher dose, of SM-EDTMP administered after count recover. 14 days after administration of higher dose, patient undergoes autologous stem cell infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10">Subject had disease progression prior to completing study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Samarium-153/Stem Cell Transplant/Radiation</title>
          <description>Samarium Sm153 Lexidronam Pentasodium/Stem Cell Transplant/Radiation arm will receive Ifosphamide IV in preparation for peripheral blood stem cell transplant followed by stem cell collection. Samarium Sm153 Lexidronam Pentasodium is administered after collection of peripheral blood stem cells. Once counts recover, while receiving filgrastim daily, a 2nd, higher dose of Samarium-153 is given, followed in 14 days by stem cell infusion.
Filgrastim: Filgrastim will be administered every day til count recovery Ifosfamide: Ifosfamide will be administered as part of Stem Cell transplant prep.
Peripheral blood stem cell transplantation: Before administration of Samarium, collection of autologous hematopoietic stem cells Radiation: Radiation Dosimetry performed at 4, 24, 48, and 72 after each infusion of Sm-EDTMP.
Samarium Sm 153 lexidronam pentasodium: First dose of Sm-EDTMP administered after autologous stem cell collection. Second, higher dose, of SM-EDTMP administered 7 days later.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" lower_limit="14" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response</title>
        <description>WHO (World Health Organization) tumor measurement criteria used to determine response.</description>
        <time_frame>1 week after study treatment</time_frame>
        <population>11 subjects, heavily treated with chemotherapy with osteosarcoma metastatic to bone were enrolled; 10 evaluable for response. Mean age: 18 years. Age range was14-30 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Samarium-153/Stem Cell Transplant/Radiation</title>
            <description>Samarium Sm153 Lexidronam Pentasodium (^153Sm-EDTMP)/Stem Cell Transplant/Radiation arm will receive Ifosphamide IV in preparation for peripheral blood stem cell transplant followed by stem cell harvest. ^153Sm-EDTMP is administered after collection of peripheral blood stem cells. Once counts recover, while receiving filgrastim daily, a 2nd, higher dose of ^153Sm-EDTMP is given, followed in 14 days by stem cell infusion.
filgrastim: Filgrastim is administered every day til count recovery.
ifosfamide: Ifosfamide is administered as part of Stem Cell transplant prep.
peripheral blood stem cell harvesting: completed before administration of ^153Sm-EDTMP, collection of autologous hematopoietic stem cells.
radiation: Radiation Dosimetry performed at 4, 24, 48, and 72 after each infusion of ^153Sm-EDTMP.
^153Sm-EDTMP: First dose is administered after autologous stem cell collection. Second, higher dose, is administered 1 week later.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>WHO (World Health Organization) tumor measurement criteria used to determine response.</description>
          <population>11 subjects, heavily treated with chemotherapy with osteosarcoma metastatic to bone were enrolled; 10 evaluable for response. Mean age: 18 years. Age range was14-30 years.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictive Value of Imaging Studies</title>
        <time_frame>At Time of Tumor Resection</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall and Progression-free Survival After Study Treatment</title>
        <time_frame>Continual</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity at End of Study Treatment</title>
        <time_frame>Continual and at End of Study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Side Effects of Infusional Samarium-153 After Study Treatment</title>
        <time_frame>Continual</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlative Dose of Radiation by Low Dose and High Dose Samarium-153</title>
        <time_frame>completion of treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks; the dose limiting toxicity was defined to be recovery of blood counts by 6 weeks post treatment with SmEDTMP (higher dose). Subjects continued to be monitored until count recovery and indefinitely for survival.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Samarium-153</title>
          <description>Cytoxan+Ifosfamide, Filgrastim pre samarium.'Sm-EDTMP (low dose). once counts recover, Sm-EDTMP (high dose) given. Peripheral blood stem cell transplantation is done 14 days later.
filgrastim: Filgrastim will be administered post post chemotherapy until target WBC count is achieved.
ifosfamide: Ifosfamide administered IV.
peripheral blood stem cell transplantation: Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
Sm-EDTMP (low dose): Sm-EDTMP (low dose) administered after autologous stem cell collection
sm-EDTMP (higher dose): Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low Platelets</sub_title>
                <description>Grade 3 or 4</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutorpenia</sub_title>
                <description>Gr 1-2: 3 subjects Gr 3-4: 5 subjects</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Gr 1: 10 subjects</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>asymptomatic. Grade 3. Resolved spontaneously.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pleural effusion</sub_title>
                <description>Gr3 increase in size of pleural effusion (disease related). This subject is not evaluable for hematologic recovery.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>&quot;Future work will focus on better understanding the factors that contribute to drug delivery and improving efficacy be combination with chemotherapy, biologics, or external beam radiotherapy.&quot; (See Publication section of this entry).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David M. Loeb, M.D., Ph.D., Director, Musculoskeletal Tumor Program</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center</organization>
      <phone>410.502.7247</phone>
      <email>loebda@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

